MedTrace Logo

Safety and Efficacy Aspects of a Standardized Stepwise Anatomical Approach for AVNRT Ablation

NCT02072473 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-10-19

No results posted yet for this study

Summary

This proposal aims to evaluate safety and efficacy aspects of a new protocol for AVNRT ablation, using a stepwise anatomical approach.

The investigators hypothesize that the use of a standardized electro-anatomical guided strategy, using a sequential approach as follows:

1. Right-side postero-septal tricuspid annulus
2. Coronary sinus
3. Left-side postero-septal mitral annulus

For slow pathway AVNRT ablation is safe and efficient, increasing the chance of a successful ablation in difficult cases, while reducing the need of re-do procedures and the risk for high-degree atrio-ventricular block.

The investigators aim to define and implement a new standardized protocol for AVNRT ablation while at the same time assessing the efficacy and safety of coronary sinus and left-side approaches for slow-pathway ablation.

Conditions

  • Re-entrant Atrioventricular Node Tachycardia

Interventions

PROCEDURE

Coronary sinus / left-sided slow pathway ablation

Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise: 1. coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by 2. left-sided slow pathway ablation, using trans-septal approach.

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Roy Beinart, MD · Sheba Medical Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072473 on ClinicalTrials.gov